Theragent and CellVax Therapeutics Announce First Manufacturing Batch in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy ...Middle East

ARCADIA, Calif., Nov. 11, 2024 /PRNewswire/ -- Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a significant milestone for both Theragent and its sponsor client, CellVax Therapeutics Inc. This past week, Theragent produced the...

Read More Details
Finally We wish PressBee provided you with enough information of ( Theragent and CellVax Therapeutics Announce First Manufacturing Batch in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy )

Also on site :

• Catholic Bishops Issue Direct Response to Trump's Polarizing Pope Photo
• ‘Saturday Night Live’ Opens With Donald Trump Signing Executive Orders, Including The “Belichick Law”: “Old Men Can Now Date Far Younger Women”
• More man-portable air defence missile systems on the way amid India-Pak tensions